Generics  

Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for Cefuroxime Axetil Tablets. Since then we have received more than 75 FDA approvals and have become one of the fastest growing pharmaceutical companies in the US. Our consistent track record of growth is a result of a valuable pipeline, solid customer relationships, and flawless execution.

We are vertically integrated, from process development of the API to the submission of dossiers for finished dosages. This provides control over the supply chain and the ability to offer quality products at the right time and at competitive prices.

Our integrated manufacturing capability provides a portfolio of the highest quality generic products.

Expanding the product portfolio, Lupin Pharmaceuticals, Inc. is geared to file 20 or more ANDA's per year in some of the following areas:

	Oral and injectable cephalosporins;
	Cardiovascular;
	Controlled release ANDA's;
	Paragraph IV's.

Lupin operates a globally integrated network of 11 manufacturing facilities. Our world class facilities are built to manufacture and deliver a wide range of finished products to the US market. All facilities are in constant compliance with quality, safety, environment standards as laid down by governments and leading regulators such as the US FDA.